

Contact:
Ami Knoefler
Spark BioComm
(650) 739-9952

**MEDITOPE BIOSCIENCES PRESENTS DATA AT THE AMERICAN ASSOCIATION
OF CANCER RESEARCH (AACR) ANNUAL MEETING VALIDATING ITS SNAP
TECHNOLOGY PLATFORM**

Pasadena, Calif., April 20, 2015 -- [Meditope Biosciences, Inc.](#), a biotechnology company developing novel antibody-based products using its proprietary technology, today announced presentation of data demonstrating the use of its SnAP technology platform for the development of antibody-drug conjugates (ADCs). The data were presented in an abstract at the AACR Annual Meeting 2015, taking place April 18-22 in Philadelphia.

“We are highly enthusiastic about these data which point to the many commercial applications that may be possible for our unique SnAP technology, including its potential to develop a powerful new generation of antibody-drug conjugate therapies,” said Elisabeth Gardiner, Meditope Biosciences’ Chief Scientific Officer and an author of the abstract. “Additionally, the attributes of these ADCs, which use SnAP technology, suggest a less complex, more efficient and predictable manufacturing approach, which can offer significant efficiencies in the drug development process.”

The abstract, titled “Improved Meditope-Based Antibody-Drug Conjugates Based on in Silico-Guided Optimization and Biological Confirmation” (Abstract #646) summarized the results of cell based assays demonstrating the structures and binding characteristics of a panel of “meditope-enabled” antibodies using Meditope’s SnAP technology platform. The data confirm the versatility of the SnAP technology for conjugation of payloads at a single site on each Fab fragment outside its antigen-binding site.

Specifically, scientists at the company demonstrated the successful transplantation of the meditope binding site to several antibodies. Meditope-peptides of different affinities were then selected by rational design and fine-tuned according to the requirements of specific application. For ADC development, data show that the meditope-peptides are conjugated with cytotoxic payloads and the higher the affinity of the meditope-peptide-drug conjugate for the antibody, the higher the complex's cytotoxic potential against antigen-positive tumor cells.

About Meditope Biosciences, Inc.

Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (**S**ite-specific **n**ovel **A**ntibody **P**latform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP is capable of turning any antibody into a proprietary, site-specific “Lego-like” system that is able to attach and detach nearly anything to an antibody without the need for chemical conjugation. Meditope’s SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. More information can be found by visiting www.meditope.com.